Other Events ·
SciSparc subsidiary completes manufacturing and QP release for Phase IIb Tourette trial
SPRCSciSparc Ltd.
Subsidiary NeuroThera Labs completed manufacturing of SCI-110 and obtained European Qualified Person batch release certification, a key regulatory milestone enabling shipment to study sites. This progress supports site activation and the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for Tourette Syndrome across three centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based treatments for central nervous system disorders.